Cancer cocktail shows promise in early trial
NCT ID NCT05945823
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior treatment will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Futibatinib (a targeted cancer drug) combined with pembrolizumab (an immunotherapy) and chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced esophageal or pancreatic cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early Phase 2 study with only 53 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance Cancer Specialists
Horsham, Pennsylvania, 19044, United States
-
Blue Ridge Cancer Care
Roanoke, Virginia, 24014, United States
-
Centre Hospitalier Regional Universitaire Poitiers
Poitiers, 86000, France
-
Centre Hospitalier Regional Universitaire de Lille
Lille, 59037, France
-
Dallas VA Medical Center
Dallas, Texas, 75216, United States
-
Gabrail Cancer Center Research LLC
Canton, Ohio, 44718, United States
-
Gundersen Lutheran Health System
La Crosse, Wisconsin, 54601, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Krankenhaus Nordwest gGmbH
Frankfurt, 60488, Germany
-
Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
NYU Langone
New York, New York, 10016, United States
-
Rocky Mountain Cancer Centers Midtown
Denver, Colorado, 80218, United States
-
Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI))
Buffalo, New York, 14203, United States
-
The Minniti Center - Medical Oncology and Hematology
Mickleton, New Jersey, 08056, United States
-
Universitaetsmedizin Mainz
Mainz, 55131, Germany
-
University of California Los Angeles UCLA - Cancer Care - Santa Monica
Santa Monica, California, 90404, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States